Conclusion GLP-1RAs show significant promise as a potential disease-modifying therapy for neurodegenerative and inflammatory eye diseases, acting through both systemic metabolic improvements and direct ocular mechanisms, representing a paradigm shift beyond their metabolic indications
GLP-1 Medications and PCOS: Fertility Benefits GLP-1 medications, originally developed for type 2 diabetes, are now showing promise in improving fertility for women with PCOS
In the STEP-1 obesity trial, semaglutide 2.4 mg weekly produced roughly 14.9% mean body-weight loss over 68 weeks ( Wilding et al., NEJM 2021 )
Its tri-agonist receptor activity supports research into receptor pharmacology, endocrine pathway regulation, lipid metabolism, hepatic signaling, and cross-tissue metabolic communication in controlled laboratory and translational research environments [1][5]
Mizumoto J
These treatments are especially beneficial for men who need help with appetite regulation, blood sugar control, and overall metabolic function